绥美凯什么时候上市的？

When was it launched? Trimax is a once-daily three-in-one drug developed by ViiV Healthcare, a joint venture between GlaxoSmithKline and Pfizer. The drug is based on the treatment regimen of the integrase inhibitor Tivicay (Dolutegravir) and also contains two nucleoside reverse transcriptase inhibitors, Abacavir and Lamivudine. It was approved by the FDA on August 27, 2014.

Subsequently, on January 22, 2018, GlaxoSmithKline (GSK) announced that its single-pill compound preparation Triumeq, which is based on the new generation integrase inhibitor dolutegravir (DTG), for the treatment of HIV, was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China.

For adults and adolescents, the recommended dose of Trimax is one tablet once daily. Adults or adolescents whose body weight is less than 40 kg should not be given this product because this product is a fixed-dose tablet and the dose cannot be reduced. Trimax is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these circumstances, physicians should refer to the respective product information for these medicines. If the patient misses a dose of Dobutanil Abalami Tablets and there are more than 4 hours before the next dose, Suimei Kai should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule. There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients aged ≥65 years, and there is no evidence that older patients require different doses than younger adults. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group.

Adverse Reactions: Clinical safety data are limited. The most commonly reported adverse reactions thought to be possibly or probably related to dolutegravir and abacavir/lamivudine (pooled data from 679 antiretroviral-naïve subjects who received this combination in phase IIb to IIIb clinical trials) were nausea (12%), insomnia (7%), dizziness (6%), and headache (6%).